NCT/Study#
NCT03564691 /
MK-4830-001
A Phase 1 Open Label, Multi-Arm, Multicenter Study Of MK-4830 As Monotherapy And In Combination With Pembrolizumab For Participants With Advanced Solid Tumors
DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
